BioCentury
ARTICLE | Clinical News

Opdivo nivolumab: Phase II/III amended

March 7, 2016 8:00 AM UTC

The Phase II/III Lung-MAP (S1400) lung cancer study added an arm that tests Opdivo nivolumab alone or in combination with Yervoy ipilimumab in patients with squamous cell lung cancer who do not have a biomarker that matches any of the study’s targeted therapies. Patients are screened using the genomic platform from Foundation Medicine Inc. (NASDAQ:FMI, Cambridge, Mass.) and assigned to treatment arms based on biomarker expression.

Lung-MAP’s targeted therapy arms are evaluating taselisib ( GDC-0032), a phosphoinositide 3-kinase (PI3K) alpha inhibitor from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY, Basel, Switzerland); Ibrance palbociclib, a small molecule cyclin dependent kinase 4 (CDK4) and CDK6 inhibitor from Pfizer Inc. (NYSE:PFE, New York, N.Y.); and AZD4547, a fibroblast growth factor (FGF) receptor (FGFR) tyrosine kinase inhibitor from AstraZeneca (LSE:AZN; NYSE:AZN, London, U.K.). ...